Tea and coffee have anti-oxidant and neuroprotective effects. Observational studies suggest that tea and coffee intake may reduce cancer risk, but data on glioma risk are inconclusive. We evaluated the association between tea, coffee, and caffeine intake and gliomarisk in the female Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII) and the male Health Professionals Follow-up Study(HPFS). Cumulative intake was derived from validated quadrennial food frequency questionnaires. Glioma cases were confirmed by medical record review. Multivariable-adjusted hazard ratios of glioma by beverage intake category were estimated using Cox proportional hazards models. We documented 554 incident cases of glioma (256 in NHS, 87 in NHSII, 211 in HPFS). Compared to <1 cup/week, higher tea consumption was borderline inversely associated with glioma risk in pooled cohorts (HR = 0.73, 95%CI: 0.49-1.10 for >2 cups/day, p-trend = 0.05), but not in women (HR = 0.74, 95% CI 0.47-1.18 for >2 cups/day, p-trend = 0.11) or men (HR = 0.70, 95%CI 0.30-1.60 for >2 cups/day, p-trend = 0.30) separately. Overall, we observed no significant associations between caffeinated, decaffeinated, or total coffee intake and glioma risk. There were no material differences in the results with baseline values, eight year lagged responses, or when limited to glioblastoma (n = 362). In three large, prospective cohort studies, tea intake was borderline inversely associated with glioma risk. No significant associations were observed for coffee intake and glioma risk. These results merit further exploration in prospective studies.
Today's Top 5
5. What Happens When Local Hospital Closes?
4. New Treatments for Childhood Cancers
3. Insomnia in Cancer Survivors
“Up to 60% of cancer survivors have some form of insomnia, but it is often underdiagnosed and undertreated. Now, people have more choices to manage their insomnia. We need to raise awareness that there are good non-drug options for this condition.” https://t.co/LC6TCYhdQM— Memorial Sloan Kettering Cancer Center (@sloan_kettering) August 21, 2019
2. Timing of ADT in Prostate Cancer
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial - The Lancet Oncology @DrSpratticus @urogeek https://t.co/pPa537AyFO— Brian F. Chapin (@ChapinMD) August 22, 2019